A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease

Annals of the Rheumatic Diseases

Volumn 65, Issue 4, 2006, Pages 508-514

  Tsukamoto, H ^a   Nagafuji, K ^a   Horiuchi, T ^a   Miyamoto, T ^a   Aoki, K ^a   Takase, K ^a   Henzan, H ^a   Himeji, D ^a   Koyama, T ^a   Miyake, K ^a   Inoue, Y ^a   Nakashima, H ^a   Otsuka, T ^a   Tanaka, Y ^b   Nagasawa, K ^c   Harada, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE HEART FAILURE; ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; DERMATOMYOSITIS; FEMALE; HERPES ZOSTER; HUMAN; MALE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; WEGENER GRANULOMATOSIS;

ADULT; ANTIGENS, CD34; AUTOIMMUNE DISEASES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DERMATOMYOSITIS; FEASIBILITY STUDIES; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 33645120856     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.037879     Document Type: Article

References (36)

1. Burt RK, Padilla J, Begolka WS, Canto MC, Miller SD. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998;91:2609-16.
2. Karussis DM, Vourka-Karussis U, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 1993;92:765-72.
3. van Bekkutn DW, Bohre EP, Houben PF, Knaan-Shanzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA 1989;86:10090-4.
4. Snowden JA, Patton WN, O'Donnell JL, Hannah EE, Hart DN. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19:1247-50.
5. Schachna L, Ryan PF, Schwerer AP. Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation. Arthritis Rheum 1998;41:2271-2.
6. Meloni G, Capria S, Vignelti M, Mandelli F, Modena V. Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation. Blood 1997;89:4659.
7. Burt RK. New indication in stem cell sources in transplantation for autoimmune diseases. Blood Marrow Transplant Reviews 2004;14:5-7.
8. Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001;60:702-7.
9. Burt RK, Arnold R, Emmons R, Oyama Y, Marmont A. Stem cell therapy for autoimmune disease: overview of concepts from the Snowbird 2002 tolerance and tissue regeneration meeting. Bone Marrow Transplant 2003;32(suppl 1):S3-5.
10. McSweeney PA, Nash RA, Sullivan KM, Stroek J, Crofford LJ, Dansey R, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcome. Blood 2002;100:1602-10.
11. Pearson CM. Polymyositis and dermatomyositis. In: McCarty DJ, ed. Arthritis and allied conditions. 9th ed. Philaderphia: Lea & Febiger, 1979:742-61.
12. Leavilt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
13. Gondo H, Harada M, Miyamoto T, Takenaka K, Tanimoto K, Mizuno S, et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1997;20:821-6.
14. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
15. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
16. Gondo H, Minematsu T, Harada M, Akashi K, Hayashi S, Taniguchi S, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994;86:130-7.
17. Oken M, Creech H, Tormey C, Horton J, Davis E, McFadden T, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
18. Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000;27:930-4.
19. Oryoji K, Himeji D, Nagafuii K, Horiuchi T, Tsukamoto H, Gondo H, et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol 2005;24:637-40.
20. 19a Daikeler T, Erley C, Mohren M, Amberger C, Einsele H, Kanz L, et al. Fever and increasing ANCA titre after kidney and autologous stem cell transplantation for Wegener's granulomatosis. Ann Rheum Dis 2005;64:646-7.
21. Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM. A phase I/II dose escalation study or intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999;42:2286-92.
22. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000;54:2147-50.
23. Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment or autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505-14.
24. Forge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81.
25. Forge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, et al. Autolougous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haemotol 2002;119:726-39.
26. Openshaw H, Nash R, McSweeny PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol Blood Marrow Transplant 2002;8:233-48.
27. Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996;88:3621-5.
28. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002;46:2301-9.
29. Saccardi R, Tyndall A, Coghlan G, Denton C, Edan G, Emidin M. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone marrow transplant 2004;34:877-881.
30. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, et al. Phase I-II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60:577-84.
31. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoaltractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165:378-81.
32. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
33. Kono H, Inokuma S. Visualization and functional consequence of pulmonary vascular impairment in patients with rheumatic diseases. Chest 2003;124:255-61.
34. Tyndall A, Gratwohl A. The use of high dose immunoablative therapy with hematopoietic stem cell support therapy in the treatment of severe autoimmune diseases. Int J Hematol 2002;76(suppl 1):218-22.
35. Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001;28:1-12.
36. Bingham SJ, Moore JJ. Stem cell transplantation for autoimmune disorders. Rheumatoid arthritis. Best Pract Res Clin Haematol 2004;17:263-76.